Recent 8-K filings for RVMD

• May 06, 2026 23:59 UTC earnings materiality 0.85 positive item 2.02item 9.01

  RevMed Q1 net loss $453.8M, daraxonrasib shows OS 13.2 mo in pancreatic cancer

  Daraxonrasib Phase 3 RASolute 302: median OS 13.2 mo vs 6.7 mo chemo (HR 0.40); NDA submission planned.

• Apr 17, 2026 23:59 UTC debt materiality 0.75 neutral item 1.01item 2.03item 8.01item 9.01

  Revolution Medicines issues $500M 0.50% convertible notes due 2033

  Issued $500M 0.50% Convertible Senior Notes due 2033 under indenture with U.S. Bank Trust as trustee.

• Apr 16, 2026 23:59 UTC other_material materiality 0.80 neutral item 8.01item 9.01

  Revolution Medicines raises ~$2.15B via equity and convertible note offerings

  Equity offering: 10,563,381 shares at $142/sh + full over-allotment of 1,584,506 shares; net proceeds ~$1.65B.

• Apr 13, 2026 23:59 UTC other_material materiality 0.90 positive item 8.01

  Revolution Medicines' daraxonrasib Phase 3 trial meets OS endpoint: 13.2 vs 6.7 months, HR 0.40

  Phase 3 RASolute 302 trial: median OS 13.2 mo vs 6.7 mo for chemo (HR 0.40, p<0.0001); PFS also statistically significant.

• Feb 25, 2026 23:59 UTC earnings materiality 0.75 neutral item 2.02item 9.01

  Revolution Medicines FY2025 net loss $1.1B; daraxonrasib Phase 3 readout on track for H1 2026

  Full year 2025 net loss $1.1B vs $600.1M in 2024; Q4 net loss $364.9M vs $194.6M.

• Nov 05, 2025 23:59 UTC earnings materiality 0.60 neutral item 2.02item 9.01

  Revolution Medicines Q3 net loss $305.2M; advancing daraxonrasib pivotal trials

  Net loss $305.2M vs $156.3M YoY; R&D expense $262.5M (+73%), G&A $52.8M (+120%).

• Oct 17, 2025 23:59 UTC regulatory materiality 0.50 positive item 8.01

  Revolution Medicines receives FDA national priority voucher for daraxonrasib

  FDA granted a non-transferrable voucher under the Commissioner's National Priority Voucher pilot program.

• Sep 10, 2025 23:59 UTC other_material materiality 0.75 positive item 8.01

  Daraxonrasib shows 35% ORR in 2L PDAC, 55% in 1L combo; Phase 3 planned

  2L PDAC: ORR 29-35% (RAS G12X and broader mutant), DCR 92-95%, median PFS 8.1-8.5 mo, median OS 13.1-15.6 mo.

• Aug 06, 2025 23:59 UTC earnings materiality 0.80 positive item 2.02item 9.01

  Revolution Medicines Q2 net loss $247.8M; advances Phase 3 RAS trials; $2B Royalty Pharma deal

  Net loss $247.8M vs $133.2M YoY; R&D expenses rose to $224.1M; FY2025 net loss guidance $1.03B-$1.09B.

• Jun 27, 2025 23:59 UTC other_material materiality 0.25 neutral item 5.07

  Revolution Medicines stockholders elect four Class II directors, ratify PwC, approve say-on-pay at 2025 annual meeting

  Directors elected: Frank Clyburn, Sandra Horning, Sushil Patel, Thilo Schroeder; each received >119M votes for.

• Jun 24, 2025 23:59 UTC debt materiality 0.85 positive item 1.01item 2.03item 7.01item 9.01

  Revolution Medicines secures up to $2B financing from Royalty Pharma, withdraws cash runway guidance

  Received $250M upfront from Royalty Pharma; up to $1.25B total synthetic royalty on daraxonrasib sales.

• Jun 18, 2025 23:59 UTC leadership materiality 0.40 neutral item 5.02

  Revolution Medicines director Barbara Weber resigns ahead of 2025 annual meeting due to Tango collaboration activation

  Barbara Weber, M.D., resigned from Revolution Medicines board effective immediately prior to June 26, 2025 annual meeting.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.75 · Most common event earnings

6 positive 0 negative 6 neutral

source · RVMD on sec.gov